AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Apr 07, 2026

To cut or not to cut? Bladder preservation takes center stage

As next-gen therapies deliver striking response rates, experts debate whether cystectomy is still essential—or becoming optional.


Professional headshot of a man wearing glasses, light blue shirt, and dark blazer with purple tie
Ashish Kamat, MD, MBBS, FACS

The latest generation of neoadjuvant chemotherapy approaches to bladder cancer has transformed bladder preservation from wishful thinking into a topic for serious discussion. Between 55% and 60% of patients undergoing radical cystectomy have no viable tumor in their bladder following neoadjuvant enfortumab vedotin + pembrolizumab or gemcitabine + cisplatin + durvalumab.  

“These regimens have, for the first time in three decades, improved survival of patients in a meaningful way,” said Ashish Kamat, MD, MBBS, FACS, endowed professor of urologic oncology and cancer research and director of the Bladder Cancer Support Program at the University of Texas MD Anderson Cancer Center in Houston, Texas. “We should not forget that it is the medical treatment, the drugs, plus the surgical treatment—the removal of the bladder—that has been shown to improve survival. If you try to pick one part of the menu and forget the other components, there’s no guarantee that patients will still live longer.” 

The reality that improved survival is associated with the combination of medical plus surgical treatment has not stopped clinicians and patients from questioning the need for cystectomy, given the apparent effectiveness of medical approaches. Clinical trials to assess prognostic factors that may predict survival independent of cystectomy are underway in Europe and the U.S. 

Dr. Kamat will moderate a Crossfire debate exploring current thinking around cystectomy and next-generation neoadjuvant regimens at the 2026 AUA Annual Meeting. Bladder Preservation After Neoadjuvant Chemotherapy With Next-Generation Treatments: Can Cystectomy Be Avoided? will highlight the opening plenary session 9:15-9:35 a.m., Friday, May 15, in Hall D of the Walter E. Washington Convention Center.  

Amy Luckenbaugh, MD, FACS, assistant professor of urology at Vanderbilt University in Nashville, Tennessee, and Shilpa Gupta, MD, director of genitourinary medical oncology at Taussig Cancer Institute and co-leader of the Genitourinary Oncology Program at Cleveland Clinic in Cleveland, Ohio, will open the session with data for and against bladder preservation. Shahrokh Shariat, MD, professor and chair of urology at the Medical University of Vienna in Austria, and Alejandro Rodriguez, MD, associate professor of urology at the Wake Forest University School of Medicine in Winston-Salem, North Carolina, will offer rebuttals. 

“The response rates are so great now, and there is actual data to argue,” Dr. Kamat said. “This is going to be an exciting debate because we don’t have to venture into the theoretical realms of philosophy to suggest that it is better for someone to live with their bladder or not. We have data and clinical trials underway. The whole debate is how we, or even can we, intelligently try to identify patients who would be in the 60% without viable tumor after these more effective treatments. Does that actually mean we avoid removing bladders?” 

Interesting Stories
Book your AUA2026 housing now
Sponsored by AUA
Book your AUA2026 housing now
Unique formulation of YONSA® (abiraterone acetate) makes it different
Sponsored by Sun Pharma
Unique formulation of YONSA® (abiraterone acetate) makes it different
AUA means business: AUA Annual Business Meeting is May 18
Sponsored by AUA
AUA means business: AUA Annual Business Meeting is May 18
Find your next big break at AUA2026
Sponsored by AUA
Find your next big break at AUA2026
More Content
Professional headshot of a man wearing glasses, pink shirt, and burgundy bow tie
Previews
Rethinking cancer detection
May 05, 2026
Pain scale gauge showing emotion faces ranging from happy green (no pain) to crying red (severe pain) with numbered indicator
Previews
The big shift
May 05, 2026
Professionals demonstrate robotic arm technology at hands-on event with participants wearing blue gloves
Previews
AUA2026 amps up hands-on skills training
May 05, 2026
Professional headshot of a man wearing glasses and business attire against a blue background
Previews
The great ablation debate
May 05, 2026
Glowing abstract sphere with horns and luminous network pattern on dark background
Previews
Bladder transplantation changes the game
Apr 21, 2026
Male surgeon in blue surgical cap and scrubs smiling at camera in hospital corridor
Previews
Scanning the best options
Apr 21, 2026
Professional headshot of a man in navy suit and striped tie with organizational pin
Previews
Separating myth from measurable outcomes
Apr 21, 2026
Illustration of a person working at a computer with robotic arms assembling digital technology above
Previews
AI: Your new interoperative partner
Apr 21, 2026
Surgical team performing minimally invasive procedure in operating room with imaging displays
Previews
Enhancing surgical vision
Apr 07, 2026
Professional headshot of a man wearing glasses and business attire against a blue background
Previews
When BPH treatments fail
Apr 07, 2026
Abstract white mesh wave pattern flowing across dark blue background with smooth, undulating curves
Previews
A scalpel-free future for kidney tumors?
Apr 07, 2026
Medical team analyzing bladder anatomy and research data on digital screen
AUA2025
P2s spotlight groundbreaking clinical trials
Apr 15, 2025
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2026 Ascend Media. All rights reserved.